sampleN.TOST | R Documentation |
Estimates the necessary sample size to obtain at least a target (desired) power.
sampleN.TOST(alpha = 0.05, targetpower = 0.8, logscale = TRUE,
theta0, theta1, theta2, CV, design = "2x2",
method = "exact", robust = FALSE, print = TRUE,
details = FALSE, imax=100)
alpha |
Significance level (one-sided). Commonly set to 0.05. |
targetpower |
Power to achieve at least. Must be >0 and <1. |
logscale |
Should the data used on log-transformed ( |
theta0 |
‘True’ or assumed T/R ratio or difference. |
theta1 |
Lower (bio-)equivalence limit. |
theta2 |
Upper (bio-)equivalence limit. |
CV |
In case of In case of cross-over studies this is the within-subject CV, in case of a parallel-group design the CV of the total variability. |
design |
Character string describing the study design. |
method |
Method for calculation of the power. |
robust |
Defaults to |
print |
If |
details |
If |
imax |
Maximum number of steps in sample size search. |
The sample size is estimated via iterative evaluation of power of the TOST procedure.
Start value for the sample size search is taken from a large sample approximation
according to Zhang, modified.
The sample size is bound to 4 as minimum.
The estimated sample size gives always the total number of subjects (not subject/sequence in crossovers or subjects/group in parallel designs – like in some other software packages).
A data frame with the input and results will be returned.
The Sample size
column contains the total sample size.
The function does not vectorize properly.
If you need sample sizes with varying CVs, use f.i. for
-loops or the apply
-family.
Of course it is highly recommended to use the default method = "exact"
. :-)
There is no reason besides testing and for comparative purposes to use an
approximation if the exact method is available at no extra costs.
D. Labes
Phillips KF. Power of the Two One-Sided Tests Procedure in Bioequivalence. J Pharmacokin Biopharm. 1990;18:137–44. \Sexpr[results=rd]{tools:::Rd_expr_doi("10.1007/BF01063556")}
Diletti D, Hauschke D, Steinijans VW. Sample Size Determination for Bioequivalence Assessment by Means of Confidence Intervals. Int J Clin Pharmacol Ther Toxicol. 1991;29(1):1–8.
Diletti D, Hauschke D, Steinijans VW. Sample size determination: Extended tables for the multiplicative model and bioequivalence ranges of 0.9 to 1.11 and 0.7 to 1.43. Int J Clin Pharmacol Ther Toxicol. 1992;30(Suppl 1):S59–62.
Zhang P. A Simple Formula for Sample Size Calculation in Equivalence Studies. J Biopharm Stat. 2003;13(3):529–38. \Sexpr[results=rd]{tools:::Rd_expr_doi("10.1081/BIP-120022772")}
power.TOST, known.designs
# Exact calculation for a classical 2x2 cross-over (TR/RT),
# BE limits 80 ... 125%, assumed true BE ratio 0.95, intra-subject CV=30%,
# using all the default values
# should give n=40 power=0.815845
sampleN.TOST(CV = 0.3)
# Exact calculation for a parallel group design
# evaluation on the original (untransformed) scale
# BE limits 80 ... 120% = -20% ... +20% of reference,
# assumed true BE ratio 0.95% = -5% to reference mean,
# total CV=20%
# should give n=48 (total) power=0.815435
sampleN.TOST(logscale = FALSE, theta1 = -0.2, theta0 = -0.05,
CV = 0.2, design = "parallel")
# A rather strange setting of theta0! Have a look at n.
# It would be better this is not the sample size but the running total
# of my bank account. But the first million is the hardest. ;-)
sampleN.TOST(CV = 0.2, theta0 = 0.8005)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.